drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous, gene-modified TCR-T cell product. Patient T cells are engineered ex vivo to express a personalized T-cell receptor matched to the patient’s HLA class I type that recognizes tumor-specific peptides; cells are expanded and reinfused to mediate cytotoxic killing via TCR/CD3 activation, perforin/granzyme release, and cytokine secretion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered ex vivo to express a personalized T-cell receptor matched to the patient’s HLA class I that recognizes tumor-specific peptides. Upon peptide–HLA engagement, TCR/CD3 signaling activates the transferred T cells to kill tumor cells via perforin/granzyme release and cytokine secretion.
drug_name
KSX01-TCRT cell therapy
nct_id_drug_ref
NCT06150365